Compare FMC Corp (FMC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs GSK plc — how do they compare? FMC Corp trades at $10.2 (market cap $1.30B), while GSK plc trades at $50.27 (market cap $102.60B). The key difference: GSK plc is far larger — about 78.9× FMC Corp's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| FMC | GSK | |
|---|---|---|
Market Cap | $1.30B | $102.60B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $61.18 |
52-Week Low | $10.01 | $38.22 |
Enterprise Value | $5.11B | $123.04B |
Dividend Yield | 3.07% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $10.17, down 2.82% today, amid bearish technical signals and weak fundamentals. Recent Q2 2026 earnings beat estimates but revenue missed, with full-year guidance lowered. The company faces significant profitability challenges, with a net income margin of -84.83% and negative ROE/ROA. Positive developments include a $400 million minority investment from Tessenderlo Group and ongoing debt reduction efforts.
The outlook remains cautious due to persistent earnings pressure and high debt levels, though asset sales and external funding provide liquidity support. Analyst consensus is mixed with a $11.60 price target, suggesting modest upside potential if operational improvements materialize. Key risks include volatile cash flows, competitive pressures, and macroeconomic headwinds affecting agricultural demand.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
